2025 CMS Updates Impacting Ambulatory Surgery Centers

Overview

In 2025, CMS finalized a 2.9% Medicare reimbursement increase for ASCs meeting quality reporting requirements, with a conversion factor of $54.895. However, reimbursement increases do not fully offset rising healthcare costs, and ASCs face new challenges including capped drug reimbursements, expiration of pass-through drug status, and expanded administrative burdens.

Background

Ambulatory Surgery Centers (ASCs) are critical providers of outpatient surgical care, including ophthalmic procedures such as cataract and blepharoplasty surgeries. Medicare reimbursement policies and quality reporting requirements significantly influence ASC operations and financial viability. Recent CMS updates aim to adjust payments and introduce new coding and reporting mandates to reflect evolving healthcare costs and priorities, including health equity. These changes require ASCs to adapt their coding, billing, and administrative processes to maintain compliance and financial sustainability.

Data Highlights

Key Findings

• CMS finalized a 2.9% Medicare reimbursement increase for ASCs that meet quality reporting requirements, with a conversion factor of $54.895 for 2025.
• Reimbursement increases for common ophthalmic procedures include +3.8% for blepharoplasty and +2.6% for cataract surgery, though these do not fully offset healthcare inflation.
• Reimbursement for nonopioid pain management drugs Omidria and Dextenza will be capped at $425.89 and $427.57 respectively, potentially increasing financial strain on ASCs.
• Pass-through status for certain ophthalmic drugs such as Xipere and Susvimo will expire by March 31, 2025, affecting separate reimbursement eligibility.
• A new permanent CPT code 66683 for iris prosthesis implantation replaces temporary codes, with revaluation and future bundling edits anticipated.
• CMS will continue voluntary reporting of ASC-11 cataract outcome measure and introduce three new health equity measures, increasing administrative reporting requirements.
• Prior authorization and step therapy requirements are expanding, with potential future CMS prior authorization pilots for ASCs, increasing administrative burdens and possible delays in patient care.

Clinical Implications

ASCs must prepare for modest Medicare reimbursement increases that do not fully cover rising costs, necessitating strategic revenue management including cash-pay services. Careful coding and billing for premium lenses and new CPT codes are essential to maximize reimbursement. The expiration of pass-through drug status and capped payments for nonopioid drugs require vigilant resource allocation. Additionally, ASCs should develop systems to comply with new health equity reporting and anticipate increased prior authorization requirements to avoid care delays.

Conclusion

The 2025 CMS updates present both opportunities and challenges for ASCs, particularly in ophthalmology. While reimbursement increases offer some financial relief, evolving drug payment policies, coding changes, and administrative requirements demand proactive adaptation to sustain high-quality outpatient surgical care.

References

1. CMS 1809-FC 2024 -- CY 2025 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule
2. OOSS 2024 -- Final 2025 ASC Payment Regulation: Facility Fees to Increase by 2.9 Percent
3. American Academy of Ophthalmology 2024 -- CMS Finalizes 2.9% Pay Increase for Hospital Outpatient, ASC Settings for 2025
4. American Academy of Ophthalmology 2024 -- 2025 Coding Update